Mitchell Mcleod Pugh & Williams Inc. Purchases 1,331 Shares of Pfizer Inc. (NYSE:PFE)

Mitchell Mcleod Pugh & Williams Inc. lifted its position in Pfizer Inc. (NYSE:PFE) by 4.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,457 shares of the biopharmaceutical company’s stock after acquiring an additional 1,331 shares during the quarter. Mitchell Mcleod Pugh & Williams Inc.’s holdings in Pfizer were worth $873,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Clarity Asset Management Inc. bought a new stake in shares of Pfizer in the 4th quarter worth $27,000. Gould Capital LLC grew its stake in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 493 shares in the last quarter. North Capital Inc. bought a new position in Pfizer during the first quarter valued at about $28,000. Bernard Wealth Management Corp. bought a new position in Pfizer during the fourth quarter valued at about $30,000. Finally, Curio Wealth LLC bought a new position in Pfizer during the fourth quarter valued at about $32,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on PFE shares. Berenberg Bank reduced their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. The Goldman Sachs Group increased their price target on shares of Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Bank of America increased their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Wolfe Research increased their price target on shares of Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a research report on Wednesday, April 30th. Finally, Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target for the company. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.55.

Pfizer Trading Down 0.5%

Shares of Pfizer stock opened at $25.65 on Monday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a market cap of $145.83 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 0.93 and a beta of 0.58. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The company’s 50-day moving average price is $23.89 and its 200-day moving average price is $24.78.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the firm posted $0.82 earnings per share. The company’s revenue for the quarter was down 7.8% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.71%. The ex-dividend date is Friday, July 25th. Pfizer’s payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.